Here is an article from Eye Doc News, a website run by 2 ophthalmologists, Dr. Ari Weitzner and Dr. Dominique Walton Brooks.
RetroSense Therapeutics is a biotechnology company using optogenetic approaches to treat retinal diseases such as retinitis pigmentosa and dry AMD.
Optogenetics refers to a technique for restoring vision that uses “opsins” to genetically convert retinal cells that were not previously, or natively light sensitive to become light sensitive, and thereby mimic the function of rods and cones.
For example, patients with retinitis pigmentosa experience progressive and irreversible vision loss because the rods and cones of their eyes die. Retrosense’s technique allows other cells in the retina (e.g., ganglion cells) to take the place of the rods and cones.
For more info, go here: http://irvaronsjournal.blogspot.com/2013/03/gene-therapy-in-ophthalmology-update-18.html
Like all genetic treatments, this should be approached with a skeptical optimism.